Q-omics provides the consensus-scored GALNT15 profile across patient tissues and cancer cell-line models. GALNT15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GALNT15 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, GALNT15 RNA expression shows 22,450 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, KICH, and BRCA as cancer lineages where GALNT15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT15 survival associations across molecular data types. GALNT15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT15 RNA expression–survival associations across cancer types. High GALNT15 expression shows unfavorable associations in CESC, STAD, BLCA and OV, but favorable associations in KIRC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GALNT15 RNA expression.
This table summarizes GALNT15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GALNT15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT15 shows lower tumor expression in KICH, KIRP, COAD, BRCA, UCEC and STAD. The KICH box plot shows higher GALNT15 RNA expression in normal versus tumor tissue (log2 FC = −2.619, t-test p < 0.001).
This table shows molecular features associated with GALNT15 in patient tissues and cancer cell lines. In patient samples, GALNT15 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
